Device Linac Solutions (Linac)

Elekta Medical Linear Accelerator

Payments companies reported to CMS as associated with Elekta Medical Linear Accelerator. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$250Kassociated payments (2023-2025)

481clinicians with associated payments

8companies reporting

By year

2023 $95K

2024 $22K

2025 $133K

Payments reported as associated with Elekta Medical Linear Accelerator, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Radiation Oncology $220K

Internal Medicine $8,767

Neurological Surgery $5,016

Dermatology $2,416

Therapeutic Radiology $1,807

Physician Assistant $936

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Elekta Medical Linear Accelerator

These are the largest totals companies reported as associated with Elekta Medical Linear Accelerator. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Robert Timmerman	Dallas, TX	Radiation Oncology	$29,542.03
Jonathan Cheng	Baytown, TX	Radiation Oncology	$20,071.81
Stephen Doggett	Newport Beach, CA	Radiation Oncology	$18,169.56
Rupesh Kotecha	Miami, FL	Radiation Oncology	$12,739.66
Anthony Paravati	Kettering, OH	Radiation Oncology	$11,497.39
Marc Posner	Lake Forest, IL	Radiation Oncology	$9,335.88
Imran Mohiuddin	Orlando, FL	Radiation Oncology	$7,983.48
Maia Hightower	Park City, UT	Internal Medicine	$7,933.56
Michael Yunes	Springfield, MA		$7,268.33
Chirag Shah	Pittsburgh, PA	Radiation Oncology	$7,111.41

Prescribed Elekta Medical Linear Accelerator?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.